CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide

Document Type : Research article

Authors

1 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Student Research Committee, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

The strong storyline behind the critical role of cyclin-dependent kinase (CDK) inhibitor proteins
in natural defense against malignant transformation not only represents a heroic perspective for
these proteins, but also provides a bright future for the application of small molecule inhibitors
of CDKs in the novel cancer treatment strategies. The results of the present study revealed that
the inhibition of CDKs using pan-CDK inhibitor AT7519, as revealed by the induction of G1
cell cycle arrest as well as the reduction of cyclins expression, resulted in decreased survival in
acute myeloid leukemia (AML)-derived KG-1 cells, either in the context of single agent or in
combination with arsenic trioxide (ATO). Apart from alterations in the expression of proliferation
and apoptotic genes, the anti-survival property of AT7519 was coupled with the inhibition of
autophagy-related genes. Notably, we found that the blockage of autophagy system in KG-1
cells resulted in a superior cytotoxic effect, introducing autophagy as a probable suppressor of
cell death. As far as we are aware, to date, no study has reported the contributory mechanisms
correlated with the less sensitivity of acute leukemia cells to AT7519 and our study suggested for
the first time that the activation of both PI3K and c-Myc signaling pathways could overshadow,
at least partly, the efficacy of this agent in KG-1 cells. Overall, due to the pharmacologic safety of
AT7519, our study proposed this inhibitor as a promising agent for the treatment of AML either
as a single agent or in a combined-modal strategy.

Keywords

Main Subjects


(1) Shapiro GI. Cyclin-dependent kinase pathways as
targets for cancer treatment. J. Clin. Oncol. (2006)
24: 1770-83.
(2) Tsatsanis C and Spandidos DA. The role of oncogenic
kinases in human cancer. Int. J. Mol. Med. (2000) 5:
583-673.
(3) Zhang H, Duan HO, Kirley SD, Zukerberg LR and
Wu CL. Aberrant splicing of cables gene, a CDK
regulator, in human cancers. Cancer Biol. Ther.
(2005) 4: 1211-5.
(4) Roy A and Banerjee S. p27 and leukemia: cell cycle
and beyond. J. Cell. Physiol. (2015) 230: 504-9.
(5) Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi
A, Tanaka K, Kurokawa M, Tanaka T, Mitani K and
Yazaki Y. Homozygous loss of the cyclin-dependent
kinase 4-inhibitor (p16) gene in human leukemias.
Blood (1994) 84: 2431-5.
Figure 7. Schematic representation proposed for the presumable mechanisms of action of AT7519
in KG-1 cells. Via abrogation of the CDK and induction of G1 cell cycle arrest, AT7519
diminished the survival and proliferative capacity of the cells plausibly through altering both cell
cycle- and apoptotic-related genes. We found that the blockage of autophagy system in KG-1 cells
resulted in a superior cytotoxic effect; introducing autophagy as a probable suppressor of cell
death.
Figure 7. Schematic representation proposed for the presumable mechanisms of action of AT7519 in KG-1 cells. Via abrogation
of the CDK and induction of G1 cell cycle arrest, AT7519 diminished the survival and proliferative capacity of the cells plausibly
through altering both cell cycle- and apoptotic-related genes. We found that the blockage of autophagy system in KG-1 cells resulted
in a superior cytotoxic effect; introducing autophagy as a probable suppressor of cell death.
130
Zabihi M et al. / IJPR (2019), 18 (Special Issue): 119-131
(6) Bose P, Simmons GL and Grant S. Cyclindependent kinase inhibitor therapy for hematologic
malignancies. Expert Opin. Inv. Drug (2013) 22:
723-38.
(7) Malumbres M, Pevarello P, Barbacid M and Bischoff
JR. CDK inhibitors in cancer therapy: what is next?
Trends Pharmacol. Sci. (2008) 29: 16-21.
(8) Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA,
Carr MG, Cross DM, Davis DJ, Devine LA, Early
TR, Feltell RE, Lewis EJ, McMenamin RL, Navarro
EF, O’Brien MA, O’Reilly M, Reule M, Saxty G,
Seavers LC, Smith DM, Squires MS, Trewartha
G, Walker MT and Woolford AJ. Identification of
N-(4-piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1
H-pyrazole-3-carboxamide (AT7519), a novel cyclin
dependent kinase inhibitor using fragment-based
X-ray crystallography and structure based drug
design. J. Med. Chem. (2008) 51: 4986-99.
(9) Dolman MEM, Poon E, Ebus ME, den Hartog IJ,
van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP,
Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron
HN and Chesler L, Molenaar JJ3.Cyclin-dependent
kinase inhibitor AT7519 as a potential drug for
MYCN-dependent neuroblastoma. Clin. Cancer
Res. (2015) 21: 5100-09.
(10) Kang MA, Kim W, Jo HR, Shin YJ, Kim MH and
Jeong JH. Anticancer and radiosensitizing effects
of the cyclin-dependent kinase inhibitors, AT7519
and SNS032, on cervical cancer. Int. J. Oncol.
(2018) 53: 703-12.
(11) Squires MS, Cooke L, Lock V, Qi W, Lewis EJ,
Thompson NT, Lyons JF and Mahadevan D.
AT7519, a cyclin-dependent kinase inhibitor, exerts
its effects by transcriptional inhibition in leukemia
cell lines and patient samples. Mol. Cancer Ther.
(2010) 9: 920-8.
(12) Wang Y, Zhi Y, Jin Q, Lu S, Lin G, Yuan H, Yang
T, Wang Z, Yao C, Ling J, Guo H, Li T, Jin J,
Li B, Zhang L, Chen Y and Lu T. Discovery of
4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-
(4-((4-methylpiperazin-1-yl)methyl)p henyl)-1Hpyrazole-3-carboxamide (FN-1501), an FLT3-
and CDK-Kinase inhibitor with potentially high
efficiency against acute myelocytic leukemia. J.
Med. Chem. (2018) 61: 1499-518.
(13) Dolman ME, den Hartog IJ, Molenaar JJ, Schellens
JH, Beijnen JH and Sparidans RW. Liquid
chromatography-tandem mass spectrometric assay
for the cyclin-dependent kinase inhibitor AT7519
in mouse plasma. J. Pharm. Biomed. Anal. (2014)
88: 216-20.
(14) Xi C, Wang L, Yu J, Ye H, Cao L and Gong Z.
Inhibition of cyclin-dependent kinases by AT7519
is effective to overcome chemoresistance in colon
and cervical cancer. Biochem. Biophys. Res.
Commun. (2019) 513: 589-93.
(15) Bayati S, Bashash D, Ahmadian S, SafaroghliAzar A, Alimoghaddam K, Ghavamzadeh A and
Ghaffari SH. Inhibition of tachykinin NK1 receptor
using aprepitant induces apoptotic cell death and
G1 arrest through Akt/p53 axis in pre-B acute
lymphoblastic leukemia cells. Eur. J. Pharmacol.
(2016) 791: 274-83.
(16) Bashash D, H Ghaffari S, Zaker F, Kazerani M,
Hezave K, Hassani S, Rostami M, Alimoghaddam K
and Ghavamzadeh A. BIBR 1532 increases arsenic
trioxide-mediated apoptosis in acute promyelocytic
leukemia cells: therapeutic potential for APL.
Anticancer Agents Med. Chem. (2013) 13: 1115-25.
(17) Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES. The history and future of targeting
cyclin-dependent kinases in cancer therapy. Nat.
Rev. Drug Discov. (2015) 14: 130.
(18) Zhao H, Jin S, Antinore MJ, Lung FD, Fan F,
Blanck P, Roller P, Fornace AJ Jr and Zhan Q.
The central region of Gadd45 is required for its
interaction with p21/WAF1. Exp. Cell Res. (2000)
258: 92-100.
(19) Zhang Y, Chen HX, Zhou SY, Wang SX, Zheng
K, Xu DD, Liu YT, Wang XY, Wang X, Yan HZ,
Zhang L, Liu QY, Chen WQ and Wang YF. Sp1 and
c-Myc modulate drug resistance of leukemia stem
cells by regulating survivin expression through
the ERK-MSK MAPK signaling pathway. Mol.
Cancer (2015) 14: 56.
(20) Castedo M, Perfettini J, Roumier T and Kroemer
G. Cyclin-dependent kinase-1: linking apoptosis
to cell cycle and mitotic catastrophe. Cell Death
Differ. (2002) 9: 1287.
(21) Sebens S, Bauer I, Geismann C, Grage-Griebenow
E, Ehlers S, Kruse ML, Arlt A and Schäfer
H. Inflammatory macrophages induce Nrf2
transcription factor-dependent proteasome activity
in colonic NCM460 cells and thereby confer antiapoptotic protection. J. Biol. Chem. (2011) 286:
40911-21.
(22) Fujiwara K, Daido S, Yamamoto A, Kobayashi
R, Yokoyama T, Aoki H, Iwado E, Shinojima N,
Kondo Y and Kondo S. Pivotal role of the cyclindependent kinase inhibitor p21WAF1/CIP1 in
apoptosis and autophagy. J. Biol. Chem. (2008)
283: 388-97.
(23) Apel A, Zentgraf H, Büchler MW and Herr I.
Autophagy—A double‐edged sword in oncology.
Int. J. Cancer (2009) 125: 991-5.
(24) Tran H, Brunet A, Grenier JM, Datta SR, Fornace
AJ Jr, DiStefano PS, Chiang LW and Greenberg
ME. DNA repair pathway stimulated by the 
131
The effect of AT7519 on KG-1 cell line
forkhead transcription factor FOXO3a through the
Gadd45 protein. Science (2002) 296: 530-4.
(25) Shao H, Mohamed EM, Xu GG, Waters M, Jing
K, Ma Y, Zhang Y, Spiegel S, Idowu MO and Fang
X. Carnitine palmitoyltransferase 1A functions to
repress FoxO transcription factors to allow cell
cycle progression in ovarian cancer. Oncotarget
(2016) 7: 3832.
(26) Tinkum KL, White LS, Marpegan L, Herzog
E, Piwnica-Worms D and Piwnica-Worms H.
Forkhead box O1 (FOXO1) protein, but not p53,
contributes to robust induction of p21 expression
in fasted mice. J. Biol. Chem. (2013) 288: 27999-
8008.
(27) Dang CV. MYC on the path to cancer. Cell (2012)
149: 22-35.
(28) Mukherjee S and Conrad SE. c-Myc suppresses
p21WAF1/CIP1 expression during estrogen
signaling and antiestrogen resistance in human
breast cancer cells. J. Biol. Chem. (2005) 280:
17617-25.
(29) McNeil CM, Sergio CM, Anderson LR, Inman
CK, Eggleton SA, Murphy NC, Millar EK, Crea
P, Kench JG, Alles MC, Gardiner-Garden M,
Ormandy CJ, Butt AJ, Henshall SM, Musgrove
EA and Sutherland RL. c-Myc overexpression and
endocrine resistance in breast cancer. J. Steroid
Biochem. Mol. Biol. (2006) 102: 147-55.
(30) Li L, Osdal T, Ho Y, Chun S, McDonald T,
Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos
Santos C, Yuan H, Ha TQ, Popa M, Hovland R,
Bruserud Ø, Gjertsen BT, Kuo YH, Chen W, Lain
S, McCormack E and Bhatia R. SIRT1 activation
by a c-MYC oncogenic network promotes the
maintenance and drug resistance of human FLT3-
ITD acute myeloid leukemia stem cells. Cell Stem
Cell (2014) 15: 431-46.
(31) Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu F,
Zhao W, Wang Y, Wu X, Da W, Wei S and Zhang
Y. c-Myc plays part in drug resistance mediated
by bone marrow stromal cells in acute myeloid
leukemia. Leuk. Res. (2015) 39: 92-9.
(32) Bush A, Mateyak M, Dugan K, Obaya A, Adachi
S, Sedivy J and Michael Cole M. c-myc null cells
misregulate cad and gadd45 but not other proposed
c-Myc targets. Genes Dev. (1998) 12: 3797-802.
(33) Schild C, Wirth M, Reichert M, Schmid RM, Saur
D and Schneider G. PI3K signaling maintains c‐
myc expression to regulate transcription of E2F1 in
pancreatic cancer cells. Mol. Carcinog. (2009) 48:
1149-58.
(34) Chan JC, Hannan KM, Riddell K, Ng PY, Peck
A, Lee RS, Hung S, Astle MV, Bywater M,
Wall M, Poortinga G, Jastrzebski K, Sheppard
KE, Hemmings BA, Hall MN, Johnstone RW,
McArthur GA, Hannan RD and Pearson RB. AKT
promotes rRNA synthesis and cooperates with
c-MYC to stimulate ribosome biogenesis in cancer.
Sci. Signal. (2011) 4: ra56-ra56.
(35) Sheikh‐Zeineddini N, Bashash D, Safaroghli‐Azar
A, Riyahi N, Shabestari RM, Janzamin E and Safa
M. Suppression of c‐Myc using 10058‐F4 exerts
caspase‐3‐dependent apoptosis and intensifies the
antileukemic effect of vincristine in pre‐B acute
lymphoblastic leukemia cells. J. Cell Biochem.
(2019) 120: 14004-16.
(36) Alipour F, Riyahi N, Safaroghli-Azar A, Sari S,
Zandi Z and Bashash D. Inhibition of PI3K pathway
using BKM120 intensified the chemo-sensitivity of
breast cancer cells to arsenic trioxide (ATO). Int. J.
Biochem. Cell Biol. (2019) 116: 105615.
(37) Bashash D, Sayyadi M, Safaroghli-Azar A,
Sheikh-Zeineddini N, Riyahi N and Momeny
M. Small molecule inhibitor of c-Myc 10058-
F4 inhibits proliferation and induces apoptosis in
acute leukemia cells, irrespective of PTEN status.
Int. J. Biochem. Cell Biol. (2019) 108: 7-16.
(38) Safaroghli-Azar A, Bashash D, Kazemi A,
Pourbagheri-Sigaroodi A and Momeny M.
Anticancer effect of pan-PI3K inhibitor on
multiple myeloma cells: Shedding new light on the
mechanisms involved in BKM120 resistance. Eur.
J. Pharmacol. (2019) 842: 89-98.
(39) Bashash D, Safaroghli-Azar A, Dadashi M, Safa M,
Momeny M and Ghaffari SH. Anti-tumor activity
of PI3K-δ inhibitor in hematologic malignant cells:
shedding new light on resistance to Idelalisib. Int.
J. Biochem. Cell Biol. (2017) 85: 149-58.
(40) Jin SV and White E. Tumor suppression by
autophagy through the management of metabolic
stress. Autophagy (2008) 4: 563-6.
(41) Wu W, Coffelt S, Cho C, Wang XJ, Lee CW, Chan
FK, Yu J and Sung JJ. The autophagic paradox in
cancer therapy. Oncogene (2012) 31: 939-53.
(42) Sheikh-Zeineddini N, Safaroghli-Azar A, Salari S
and Bashash D. C-Myc inhibition sensitizes pre-B
ALL cells to the anti-tumor effect of vincristine
by altering apoptosis and autophagy: Proposing a
probable mechanism of action for 10058-F4. Eur.
J. Pharmacol. (2019) 870: 172821.
(43) Riyahi N, Safaroghli-Azar A, Sheikh-Zeineddini N,
Sayyadi M and Bashash D. Synergistic Effects of
PI3K and c-Myc Co-targeting in Acute Leukemia:
Shedding New Light on Resistance to Selective
PI3K-δ Inhibitor CAL-101. Cancer Invest. (2019)
37: 311-24.